Identification and evaluation of microbiome-based therapies to tackle cachexia in acute myeloid leukemia

Lecop, Sophie
(2026)

Files

Thesis_September_2026_LECOP_Sophie.pdf
  • Closed Access
  • Adobe PDF
  • 428.05 MB
  • https://creativecommons.org/licenses/by-nc-nd/4.0/
Request a copy

Details

Authors
Supervisors
Bindels, Laure  
Abstract
(en) Acute myeloid leukemia (AML) is a hematological malignancy associated with muscle wasting, a key feature of cancer cachexia, a multifactorial syndrome lacking effective standard treatment. Emerging evidence suggests that the gut microbiome may represent a therapeutic target. In this thesis, we identify two potential probiotics, Odoribacter splanchnicus and Gemmiger formicilis, which disappearance following intensive AML treatment was associated with impaired gut barrier function and body weight loss respectively. Moreover, we demonstrate that culture supernatants from multiple strains of Lachnospira eligens counteract myotube atrophy, an effect driven by the end-products of anaerobic mixed-acid fermentation, acetate, formate, and D-lactate. Concordantly, treatment-naïve AML patients exhibit reduced blood acetate levels and microbiome signatures suggesting altered gut O2 levels. Collectively, these results support the development of microbiome-based strategies to tackle cachexia in AML.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lecop, S. (2026). Identification and evaluation of microbiome-based therapies to tackle cachexia in acute myeloid leukemia. https://hdl.handle.net/2078.5/280570